Literature DB >> 26104826

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Carolyn I Rodriguez1, Lawrence S Kegeles2, Amanda Levinson3, R Todd Ogden4, Xiangling Mao5, Matthew S Milak6, Donna Vermes6, Shan Xie7, Liane Hunter8, Pamela Flood9, Holly Moore6, Dikoma C Shungu10, Helen B Simpson6.   

Abstract

We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD). This study examined the concurrent neurochemical effects of ketamine versus saline infusions using proton magnetic resonance spectroscopy ((1)H MRS) during the clinical proof-of-concept crossover trial. Levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and the excitatory neurochemicals glutamate+glutamine (Glx) were acquired in the medial prefrontal cortex (MPFC), a region implicated in OCD pathology. Seventeen unmedicated OCD adults received two intravenous infusions at least 1 week apart, one of saline and one of ketamine, while lying supine in a 3.0 T GE MR scanner. The order of each infusion pair was randomized. Levels of GABA and Glx were measured in the MPFC before, during, and after each infusion and normalized to water (W). A mixed effects model found that MPFC GABA/W significantly increased over time in the ketamine compared with the saline infusion. In contrast, there were no significant differences in Glx/W between the ketamine and saline infusions. Together with earlier evidence of low cortical GABA in OCD, our findings suggest that models of OCD pathology should consider the role of GABAergic abnormalities in OCD symptomatology.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gamma-aminobutyric acid; Glutamate–glutamine; Ketamine; Magnetic resonance spectroscopy; Medial prefrontal cortex; Obsessive-compulsive disorder (OCD)

Mesh:

Substances:

Year:  2015        PMID: 26104826      PMCID: PMC4715460          DOI: 10.1016/j.pscychresns.2015.06.001

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  51 in total

Review 1.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2012-02-21       Impact factor: 9.306

2.  Time-domain combination of MR spectroscopy data acquired using phased-array coils.

Authors:  Mark A Brown
Journal:  Magn Reson Med       Date:  2004-11       Impact factor: 4.668

3.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Authors:  Lawrence S Kegeles; Xiangling Mao; Arielle D Stanford; Ragy Girgis; Najate Ojeil; Xiaoyan Xu; Roberto Gil; Mark Slifstein; Anissa Abi-Dargham; Sarah H Lisanby; Dikoma C Shungu
Journal:  Arch Gen Psychiatry       Date:  2012-01-02

4.  Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder.

Authors:  Gwyneth Zai; Paul Arnold; Eliza Burroughs; Cathy L Barr; Margaret A Richter; James L Kennedy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-04-05       Impact factor: 3.568

5.  Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia.

Authors:  Gwyneth Zai; Nicole King; Gregory W H Wong; Cathy L Barr; James L Kennedy
Journal:  Eur Neuropsychopharmacol       Date:  2005-05       Impact factor: 4.600

6.  Reproducibility of prefrontal γ-aminobutyric acid measurements with J-edited spectroscopy.

Authors:  Matthew Geramita; Jan Willem van der Veen; Alan S Barnett; Antonina A Savostyanova; Jun Shen; Daniel R Weinberger; Stefano Marenco
Journal:  NMR Biomed       Date:  2011-02-03       Impact factor: 4.044

7.  Corticostriatal interactions in the generation of tic-like behaviors after local striatal disinhibition.

Authors:  Vladimir Pogorelov; Meiyu Xu; Haleigh R Smith; Gordon F Buchanan; Christopher Pittenger
Journal:  Exp Neurol       Date:  2015-01-15       Impact factor: 5.330

8.  Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.

Authors:  B D Greenberg; J Benjamin; J D Martin; D Keuler; S J Huang; M Altemus; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1998-12       Impact factor: 4.530

9.  Driving fast-spiking cells induces gamma rhythm and controls sensory responses.

Authors:  Jessica A Cardin; Marie Carlén; Konstantinos Meletis; Ulf Knoblich; Feng Zhang; Karl Deisseroth; Li-Huei Tsai; Christopher I Moore
Journal:  Nature       Date:  2009-04-26       Impact factor: 49.962

Review 10.  The neural bases of obsessive-compulsive disorder in children and adults.

Authors:  Tiago V Maia; Rebecca E Cooney; Bradley S Peterson
Journal:  Dev Psychopathol       Date:  2008
View more
  13 in total

1.  Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.

Authors:  Shibany P Taormina; Matthew P Galloway; David R Rosenberg
Journal:  J Dev Behav Pediatr       Date:  2016 Jul-Aug       Impact factor: 2.225

2.  Brain γ-aminobutyric acid (GABA) detection in vivo with the J-editing (1) H MRS technique: a comprehensive methodological evaluation of sensitivity enhancement, macromolecule contamination and test-retest reliability.

Authors:  Dikoma C Shungu; Xiangling Mao; Robyn Gonzales; Tacara N Soones; Jonathan P Dyke; Jan Willem van der Veen; Lawrence S Kegeles
Journal:  NMR Biomed       Date:  2016-05-13       Impact factor: 4.044

Review 3.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

4.  Lower excitatory synaptic gene expression in orbitofrontal cortex and striatum in an initial study of subjects with obsessive compulsive disorder.

Authors:  Sean C Piantadosi; Brittany L Chamberlain; Jill R Glausier; David A Lewis; Susanne E Ahmari
Journal:  Mol Psychiatry       Date:  2019-06-05       Impact factor: 15.992

5.  Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

6.  Effects of common anesthetic agents on [18F]flumazenil binding to the GABAA receptor.

Authors:  Mikael Palner; Corinne Beinat; Sam Banister; Francesca Zanderigo; Jun Hyung Park; Bin Shen; Trine Hjoernevik; Jae Ho Jung; Byung Chul Lee; Sang Eun Kim; Lawrence Fung; Frederick T Chin
Journal:  EJNMMI Res       Date:  2016-11-08       Impact factor: 3.138

Review 7.  From Thought to Action: How the Interplay Between Neuroscience and Phenomenology Changed Our Understanding of Obsessive-Compulsive Disorder.

Authors:  J Bernardo Barahona-Corrêa; Marta Camacho; Pedro Castro-Rodrigues; Rui Costa; Albino J Oliveira-Maia
Journal:  Front Psychol       Date:  2015-11-23

8.  Serum Cytokine Profiles of Children with Obsessive-Compulsive Disorder Shows the Evidence of Autoimmunity.

Authors:  Şeref Şimşek; Tuğba Yüksel; Abdullah Çim; Savaş Kaya
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

Review 9.  Ketamine: 50 Years of Modulating the Mind.

Authors:  Linda Li; Phillip E Vlisides
Journal:  Front Hum Neurosci       Date:  2016-11-29       Impact factor: 3.169

10.  Effect of Ketamine on Limbic GABA and Glutamate: A Human In Vivo Multivoxel Magnetic Resonance Spectroscopy Study.

Authors:  Leo R Silberbauer; Benjamin Spurny; Patricia Handschuh; Manfred Klöbl; Petr Bednarik; Birgit Reiter; Vera Ritter; Patricia Trost; Melisande E Konadu; Marita Windpassinger; Thomas Stimpfl; Wolfgang Bogner; Rupert Lanzenberger; Marie Spies
Journal:  Front Psychiatry       Date:  2020-09-08       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.